Our results are consistent with recent publications in several preclinical glioma models and other tumor types such as malignant rhabdoid tumors noting that Ink4a-ARF loss is a biomarker for response to PD-0332991 [17-21]. The gene discussed is CDKN2A; the disease is glioma.